Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
06:01am, Friday, 10'th May 2024
A commonly used strategy for investing is sector rotation. This involves the movement of funds from one sector to another based on macroeconomic and other factors.
Safeguard Your Future: Top 3 Stocks to Weather Any Market Downturn
08:12pm, Thursday, 09'th May 2024
An investor needs to be looking for stocks that can ride out a period of general downturn in the market. Three key players come to mind, each offering its own investment opportunity as a store of va
3 Profitable Dividend Stocks to Buy at Near-Lows
01:55pm, Thursday, 09'th May 2024
Undervalued dividend stocks present two return routes: price appreciation or dividend payments that add to income. As of this writing, the market has some attractive dividend opportunities you buy.
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
10:34am, Thursday, 09'th May 2024
Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).
2 No-Brainer Dividend Stocks to Buy in May
08:15am, Thursday, 09'th May 2024
Dividend stocks have delivered the bulk of U.S. stock market returns since 1960. AT&T and Pfizer stand out as incredible bargains for income and value investors alike.
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
04:37am, Thursday, 09'th May 2024
Shares of Pfizer offer a 6% dividend yield at recent prices. The pharmaceutical giant has raised its quarterly payout for 15 consecutive years.
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer
11:57am, Wednesday, 08'th May 2024
The lawsuits were filed in state courts nationwide, but the agreements don't completely resolve Pfizer's exposure to claims linking Zantac and cancer.
Pfizer: A 6% Yield And At 10-Year Lows
10:37am, Wednesday, 08'th May 2024
Pfizer's stock has experienced significant fluctuations in the past 4 years, with opportunities for investors to buy low and sell high. The market has driven Pfizer's price to a 10-year low. Pfizer's
Here's why you should buy these 3 stocks and hold them forever
09:38am, Wednesday, 08'th May 2024
Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack o
Pfizer reports patient death in Duchenne gene therapy study
05:04pm, Tuesday, 07'th May 2024
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told
Pfizer Dividend Yield Pushes Past 6%
03:25pm, Tuesday, 07'th May 2024
In trading on Tuesday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.91 on the day. Dividends are
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
02:04pm, Tuesday, 07'th May 2024
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
02:22pm, Monday, 06'th May 2024
Investing in dividend stocks is one of the surest paths to building long-term wealth. Those who reinvest dividends compound their returns, building sustainable wealth in the long run.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
10:01am, Monday, 06'th May 2024
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
06:10am, Monday, 06'th May 2024
Biopharma giant Pfizer Inc. NYSE: PFE has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to its sw
